ClinicalTrials.gg
Status unknownNCT01417897HERMESUpdated Mar 5, 2012

Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study

A Phase 4 interventional study of Insulin glulisine and Insulin aspart in Type 2 Diabetes Mellitus, sponsored by ikfe-CRO GmbH. Status unknown at 1 site in Germany. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-03-05.

Sponsored by ikfe-CRO GmbH · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2012), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus, Type 2.

Planned enrollment
25th of 25
12 · median 281
Started
2011
with 1 other
Phase 4
14 of 26
none open now
Registered
22nd of 26
by date
Lead sponsor
2 of 26
ikfe-CRO GmbH

Among the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2, this one is the 25th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2011, is one of 14 in phase 4, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing insulin glulisine in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The planned HERMES study is to investigate and compare the effects of Insulin Glulisine, Insulin Aspart and regular human insulin on postprandial nitrotyrosine concentrations and several clinical and laboratory markers of postprandial endothelial cell function, sub-clinical inflammation and cardiovascular risk in patients with type 2 DM. The primary parameter in this study are the postprandial changes in the nitrotyrosine concentrations, a biomarker for oxidative stress. As vascular data on Insulin Glulisine vs. Insulin Aspart are missing, it is not possible to calculate sample size and statistical power. Therefore the goal of the HERMES-Pilot-Study is to generate preliminary data for statistical considerations and estimations on the probability of success of HERMES.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • Stable BOT (basal oral therapy) with Insulin Glargine + ≥ 2 OHA (oral hypoglycemic agents except for TZD) for a minimum of three months before entering the study
  • ≤ 8.5%
  • Age between 30 and 75 years inclusively
  • ≤ 40 kg/m2
  • Patient consents that his/her family physician will be informed of trial participation

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Unspecific infection or inflammation (hsCRP >10mg/L in POC test)
  • Use of thiazolidinediones within the last 3 months prior to study start
  • Retinopathy, hepatic or renal dysfunction or other major diseases
  • History of drug or alcohol abuse within the last five years prior to screening
  • History of to the study drugs (or any component of the study drug) or to drugs with similar chemical structures
  • History of severe or multiple allergies
  • Treatment with any other drug within 3 months prior to screening
  • Progressive fatal disease
  • hepatic (ALAT and/or ASAT > 3 times the normal reference range), renal (creatinine > 1.3 mg/dl in women and > 1.6 mg/dl in men), neurological, psychiatric and/or hematological disease as judged by the investigator
  • Pregnant or lactating women
  • Sexually active women of not consistently and correctly practicing by implants, injectables, combined oral contraceptives, hormonal intrauterine devices (IUDs), sexual abstinence or vasectomized partner
  • Lack of compliance or other similar reason that, according to investigator, precludes satisfactory participation in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Insulin Glulisine: bolus injections before each main meal

    Patients are already on an Insulin Glargine therapy when they start and will them after randomization receive additionally Insulin Glulisine bolus injections before each of the main meals.

    Drug: Insulin glulisine

  • Active comparator
    Insulin Aspart: bolus injections before each main meal

    Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally Insulin Aspart bolus injections before each of the main meals.

    Drug: Insulin aspart

  • Active comparator
    Regular human insulin:bolus injections before each main meal

    Patients are already on an Insulin Glargine ± metformin therapy when they start the start and will them after randomization receive additionally regular human insulin bolus injections before each of the main meals.

    Drug: Regular human insulin

Interventions

  • Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.

    Also known as: Apidra

  • Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.

    Also known as: NovoRapid

  • Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.

    Also known as: InsumanRapid

06

What researchers measure

Primary outcomes

  1. Nitrotyrosine

    The difference in the percent increase of the oxidative stress biomarker nitrotyrosine after stimulation with a standardized meal

    Time frame: Baseline, after 10 weeks, after 24 weeks

Secondary outcomes

  1. Skin blood flow

    Change in skin blood flow during stimulation by a standardized meal

    Time frame: Baseline, after 10 weeks, after 24 weeks

  2. mRNA expression of proinflammatory cytokines (MAPK/eNOS, adiponectin, hsCRP, MMP-9)

    Biomarkers of sub-clinical inflammation and cardiovascular risk: Change in Macrophage activation, MAPK/eNOS production levels, adiponectin and hsCRP (after test meal) from baseline to endpoint

    Time frame: Baseline, after 10 weeks, after 24 weeks

  3. Insulin

    Change in Insulin and the ratio from baseline to endpoint

    Time frame: Baseline, after 10 weeks, after 24 weeks

  4. HbA1c

    Blood glucose control: Change during test meal, HbA1c and FBG from baseline to endpoint

    Time frame: Baseline, after 10 weeks, after 24 weeks

  5. Fasting blood glucose

    Blood glucose control: Change during test meal, HbA1c and FBG from baseline to endpoint

    Time frame: Baseline, after 10 weeks, after 24 weeks

  6. Hypoglycemic events

    Incidence of hypoglycemia from baseline to endpoint

    Time frame: Baseline, after 10 weeks, after 24 weeks

  7. intact Proinsulin

    Change in intact Proinsulin and the ratio from baseline to endpoint

    Time frame: Baseline, after 10 weeks, after 24 weeks

07

Study locations

1 site
  • ife GmbH, Clinic
    Mainz, Rhineland-Palatinate 55116, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2011
First posted
Aug 16, 2011
Start
Sep 2011
Primary completionEst.
May 2012
CompletionEst.
May 2012
Last update
Mar 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01417897
Lead sponsor
ikfe-CRO GmbH
Collaborators
IKFE Institute for Clinical Research and Development
Responsible party
Marcus Borchert (Thomas Forst, MD PhD, ikfe GmbH, Clinic, ikfe-CRO GmbH) — Principal investigator
First posted
Aug 16, 2011
Start date
Sep 2011
Primary completion
May 2012 (estimated)
Completion
May 2012 (estimated)
Last update
Mar 5, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin glulisine

Start the discussion